128 related articles for article (PubMed ID: 21244412)
1. Adverse events and health status following botulinum toxin type A injections in children with cerebral palsy.
O'Flaherty SJ; Janakan V; Morrow AM; Scheinberg AM; Waugh MC
Dev Med Child Neurol; 2011 Feb; 53(2):125-30. PubMed ID: 21244412
[TBL] [Abstract][Full Text] [Related]
2. Systemic adverse events following botulinum toxin A therapy in children with cerebral palsy.
Naidu K; Smith K; Sheedy M; Adair B; Yu X; Graham HK
Dev Med Child Neurol; 2010 Feb; 52(2):139-44. PubMed ID: 20412252
[TBL] [Abstract][Full Text] [Related]
3. Adverse events following botulinum toxin type A treatment in children with cerebral palsy.
Langdon K; Blair E; Davidson SA; Valentine J
Dev Med Child Neurol; 2010 Oct; 52(10):972-3; author reply 974. PubMed ID: 20561011
[No Abstract] [Full Text] [Related]
4. Botulinum toxin: does the black box warning justify change in practice?
Narayanan UG
Dev Med Child Neurol; 2011 Feb; 53(2):101-2. PubMed ID: 21244406
[No Abstract] [Full Text] [Related]
5. Severity of cerebral palsy and likelihood of adverse events after botulinum toxin A injections.
Swinney CM; Bau K; Burton KLO; O'Flaherty SJ; Bear NL; Paget SP
Dev Med Child Neurol; 2018 May; 60(5):498-504. PubMed ID: 29451702
[TBL] [Abstract][Full Text] [Related]
6. The key-muscle concept: a long-term low-dose injection strategy for botulinum toxin A treatment in cerebral palsy.
Placzek R; Salem KH; Meiss LA; Siebold D; Drescher W
Acta Orthop Belg; 2012 Feb; 78(1):111-6. PubMed ID: 22523937
[TBL] [Abstract][Full Text] [Related]
7. Botulinum toxin a injections to the upper limbs in children with cerebral palsy: duration of effect.
Fattal-Valevski A; Sagi L; Domenievitz D
J Child Neurol; 2011 Feb; 26(2):166-70. PubMed ID: 20929909
[TBL] [Abstract][Full Text] [Related]
8. Systemic adverse events after botulinum neurotoxin A injections in children with cerebral palsy.
Paget SP; Swinney CM; Burton KLO; Bau K; O'Flaherty SJ
Dev Med Child Neurol; 2018 Nov; 60(11):1172-1177. PubMed ID: 30146721
[TBL] [Abstract][Full Text] [Related]
9. Determinants of responsiveness to botulinum toxin, casting, and bracing in the treatment of spastic equinus in children with cerebral palsy.
Yap R; Majnemer A; Benaroch T; Cantin MA
Dev Med Child Neurol; 2010 Feb; 52(2):186-93. PubMed ID: 20412253
[TBL] [Abstract][Full Text] [Related]
10. Functional impairment severity is associated with health status among older persons with intellectual disability and cerebral palsy.
Henderson CM; Rosasco M; Robinson LM; Meccarello J; Janicki MP; Turk MA; Davidson PW
J Intellect Disabil Res; 2009 Nov; 53(11):887-97. PubMed ID: 19732278
[TBL] [Abstract][Full Text] [Related]
11. Use of intramuscular botulinum toxin in Malaysian children with cerebral palsy.
Khoo TB; Yusniza MY; Chern PM
Med J Malaysia; 2007 Mar; 62(1):3-5. PubMed ID: 17682560
[TBL] [Abstract][Full Text] [Related]
12. The short-term effects of combined modified constraint-induced movement therapy and botulinum toxin injection for children with spastic hemiplegic cerebral palsy.
Park ES; Rha DW; Lee JD; Yoo JK; Chang WH
Neuropediatrics; 2009 Dec; 40(6):269-74. PubMed ID: 20446220
[TBL] [Abstract][Full Text] [Related]
13. Botulinum toxin A in the management of spastic gait disorders in children and young adults with cerebral palsy: a randomized, double-blind study of "high-dose" versus "low-dose" treatment.
Wissel J; Heinen F; Schenkel A; Doll B; Ebersbach G; Müller J; Poewe W
Neuropediatrics; 1999 Jun; 30(3):120-4. PubMed ID: 10480205
[TBL] [Abstract][Full Text] [Related]
14. [Botulinum A in the treatment of equinus dynamic spasticity in children with cerebral palsy. Preliminary study].
Mousny M; Allington N
Rev Chir Orthop Reparatrice Appar Mot; 1999 May; 85(2):156-63. PubMed ID: 10392416
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the effectiveness of botulinum toxin injections in the lower limb muscles of children with cerebral palsy. Preliminary prospective study of the advantages of ultrasound guidance.
Py AG; Zein Addeen G; Perrier Y; Carlier RY; Picard A
Ann Phys Rehabil Med; 2009 Apr; 52(3):215-23. PubMed ID: 19447084
[TBL] [Abstract][Full Text] [Related]
16. [Botulinum toxin type A (dysport) in the complex rehabilitation of children with spastic forms of cerebral palsy].
Zmanovskaia VA; Levitina EV; Popkov DA; Butorina MN; Pavlova OL
Zh Nevrol Psikhiatr Im S S Korsakova; 2014; 114(7):33-6. PubMed ID: 25176264
[TBL] [Abstract][Full Text] [Related]
17. Prospective study examining remote effects of botulinum toxin a in children with cerebral palsy.
Crowner BE; Racette BA
Pediatr Neurol; 2008 Oct; 39(4):253-8. PubMed ID: 18805363
[TBL] [Abstract][Full Text] [Related]
18. Effect of botulinum toxin in the treatment of drooling: a controlled clinical trial.
Jongerius PH; van den Hoogen FJ; van Limbeek J; Gabreëls FJ; van Hulst K; Rotteveel JJ
Pediatrics; 2004 Sep; 114(3):620-7. PubMed ID: 15342830
[TBL] [Abstract][Full Text] [Related]
19. Upper extremity function and occupational performance in children with spastic cerebral palsy following lower extremity botulinum toxin injections.
Keren-Capelovitch T; Jarus T; Fattal-Valevski A
J Child Neurol; 2010 Jun; 25(6):694-700. PubMed ID: 20508235
[TBL] [Abstract][Full Text] [Related]
20. [Botulinum toxin in the management of spastic hip adductors in non-ambulatory cerebral palsy children].
Deleplanque B; Lagueny A; Flurin V; Arnaud C; Pedespan JM; Fontan D; Pontallier JR
Rev Chir Orthop Reparatrice Appar Mot; 2002 May; 88(3):279-85. PubMed ID: 12037484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
